The valuation assigned is $3.26 on an undiluted basis and $2.13 on a fully diluted basis. They have Melanoma & CCRCC program assumptions which are incorrect. I feel like I spent time 10 mins reading this report which I will not get back.
Dr.T - is it the 100% success potential that MST has assigned to RC220 that prompted you to send a newsletter? Apart from that, it reads like a nice fiction.
Ann: Race In-person Investor Briefing Invitation Perth, page-23
-
- There are more pages in this discussion • 108 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
